INmune Bio presents preclinical data at SITC 2023 on INB03

INmune Bio is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biologia y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4. The poster entitled “INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages,” shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPalpha-CD47 pathway to promote ADCP. SIRPalpha is a surface protein expressed by macrophages that binds to CD47 expressed by tumor cells. SIRPalpha-CD47 is known as the “don’t eat me” signal that prevents phagocytosis of tumor cells and promotes resistance to immunotherapy. INB03 downregulates SIRPalpha expression to eliminate the “don’t eat me signal” and promote ADCP. Inhibition of the SIRPalpha-CD47 pathway has focused predominately on targeting CD47 with anti-CD47 therapeutics. Targeting SIRPalpha may provide differentiated pharmacokinetic, safety, and efficacy profiles.